By enabling controlled activation of Gasdermin or RIPK1/3–MLKL pathways, such platforms can enhance tumor-specific immune activation while limiting systemic diffusion of DAMPs and minimizing collateral damage to normal tissues. The gene discussed is GSDMA; the disease is neoplasm.